These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
636 related articles for article (PubMed ID: 27956228)
21. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783 [TBL] [Abstract][Full Text] [Related]
22. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136 [TBL] [Abstract][Full Text] [Related]
23. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis. Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820 [TBL] [Abstract][Full Text] [Related]
24. Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration. Zhang S; Nguyen LH; Zhou K; Tu HC; Sehgal A; Nassour I; Li L; Gopal P; Goodman J; Singal AG; Yopp A; Zhang Y; Siegwart DJ; Zhu H Gastroenterology; 2018 Apr; 154(5):1421-1434. PubMed ID: 29274368 [TBL] [Abstract][Full Text] [Related]
25. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Dudgeon C; Peng R; Wang P; Sebastiani A; Yu J; Zhang L Oncogene; 2012 Nov; 31(46):4848-58. PubMed ID: 22286758 [TBL] [Abstract][Full Text] [Related]
26. Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively. Zhou X; Li R; Jing R; Zuo B; Zheng Q J Cancer Res Clin Oncol; 2020 Jun; 146(6):1509-1521. PubMed ID: 32266537 [TBL] [Abstract][Full Text] [Related]
28. Regulatory factor X5 promotes hepatocellular carcinoma progression by transactivating tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta and suppressing apoptosis. Chen DB; Zhao YJ; Wang XY; Liao WJ; Chen P; Deng KJ; Cong X; Fei R; Wu X; Shao QX; Wei L; Xie XW; Chen HS Chin Med J (Engl); 2019 Jul; 132(13):1572-1581. PubMed ID: 31188160 [TBL] [Abstract][Full Text] [Related]
29. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520 [TBL] [Abstract][Full Text] [Related]
30. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996 [TBL] [Abstract][Full Text] [Related]
31. Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1. Martínez-López N; García-Rodríguez JL; Varela-Rey M; Gutiérrez V; Fernández-Ramos D; Beraza N; Aransay AM; Schlangen K; Lozano JJ; Aspichueta P; Luka Z; Wagner C; Evert M; Calvisi DF; Lu SC; Mato JM; Martínez-Chantar ML Gastroenterology; 2012 Sep; 143(3):787-798.e13. PubMed ID: 22687285 [TBL] [Abstract][Full Text] [Related]
32. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma. Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956 [No Abstract] [Full Text] [Related]
33. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312 [TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma. Khan MGM; Ghosh A; Variya B; Santharam MA; Ihsan AU; Ramanathan S; Ilangumaran S BMC Cancer; 2020 Aug; 20(1):774. PubMed ID: 32807134 [TBL] [Abstract][Full Text] [Related]
35. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer. Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835 [TBL] [Abstract][Full Text] [Related]
36. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report. Gao L; Shay C; Lv F; Wang X; Teng Y Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785 [TBL] [Abstract][Full Text] [Related]
37. Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice. Huang W; Chen Z; Zhang L; Tian D; Wang D; Fan D; Wu K; Xia L Gastroenterology; 2015 Oct; 149(4):1053-67.e14. PubMed ID: 26065367 [TBL] [Abstract][Full Text] [Related]
38. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma. Sun W; He B; Yang B; Hu W; Cheng S; Xiao H; Yang Z; Wen X; Zhou L; Xie H; Shen X; Wu J; Zheng S Lab Invest; 2018 Jun; 98(6):734-744. PubMed ID: 29467456 [TBL] [Abstract][Full Text] [Related]
39. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway. Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171 [TBL] [Abstract][Full Text] [Related]
40. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]